5-hydroxypent-2-ynoic acid ethyl ester | 90512-13-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-hydroxypent-2-ynoic acid ethyl ester
• 英文别名: ethyl 5-hydroxypent-2-ynoate；5-Hydroxy-pent-2-insaeure-aethylester；2-Pentynoic acid, 5-hydroxy-, ethyl ester
• CAS: 90512-13-3
• 化学式: C₇H₁₀O₃
• 分子量: 142.155
• InChiKey: KNCDIZYTJUXNDA-UHFFFAOYSA-N

物化性质

• 沸点：
  90 °C(Press: 0.2 Torr)
• 密度：
  1.107±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-hydroxypent-2-ynoic acid ethyl ester 在 氘 作用下， 以 氘代甲醇-d 为溶剂， 生成 ethyl 2,2,3,3-d4-5-hydroxypentanoate
  参考文献：
  名称：

  [EN] PROSTACYCLIN DERIVATIVES
  [FR] DÉRIVÉS DE PROSTACYCLINE

  摘要：

  本发明涉及新的前列腺素I2衍生物及其可接受的盐。该发明还提供了包含本发明化合物的组合物，以及将这些组合物用于治疗通过前列腺素I2有益治疗的疾病和状况的方法，特别是那些通过全身和肺动脉血管床扩张剂或通过血小板聚集抑制剂有益治疗的疾病和状况。

  公开号：

  WO2011003058A1
• 作为产物：
  描述：

  5-(tetrahydro-pyran-2-yloxy)-pent-2-ynoic acid ethyl ester 在 4-甲基苯磺酸吡啶 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以1.52 g的产率得到5-hydroxypent-2-ynoic acid ethyl ester
  参考文献：
  名称：

  Ruthenium(II)-Catalyzed Cyclization of Azabenzonorbornadienes with Alkynes

  摘要：

  The ruthenium-catalyzed cyclization of azabenzonorbornadienes with alkynes leads to an unanticipated dihydrobenzoindole framework. Depending on the structure of the alkyne and the Ru catalyst, either a dihydrobenzoindole and/or a [2+2] cycloaddition product could be formed. Cp*Ru(COD)Cl was found to be an active catalyst for the cyclization of an azabenzonorbornadiene with a propargylic alcohol to produce the dihydrobenz[g]indole as a single regio and stereoisomer in good yield. For other alkynes, selective formation of the dihydrobenz[g]indole is possible by using a cationic Ru catalyst, [Cp*Ru(CH3CN)(3)]PF6.

  DOI：

  10.1021/ol0712531

文献信息

• SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
  申请人：CAO Bin

  公开号：US20100075994A1

  公开（公告）日：2010-03-25

  The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢和四氢噁唑嘧啶酮，具体地说，涉及一系列式(I)的2-取代-2,3-二氢-噁唑并[3,2-a]嘧啶-7-酮和2-取代-2,3,5,6-四氢-噁唑并[3,2-a]嘧啶-7-酮： 其中p、n、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物在药物制剂中具有用途，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面，包括但不限于急性和慢性神经退行性疾病、精神病、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐。
• Total Synthesis of Bryostatins: The Development of Methodology for the Atom-Economic and Stereoselective Synthesis of the Ring C Subunit
  作者：Barry M. Trost、Alison J. Frontier、Oliver R. Thiel、Hanbiao Yang、Guangbin Dong

  DOI：10.1002/chem.201002898

  日期：2011.8.22

  for the stereoselective assembly of the ring C subunit were developed. A Pd‐catalyzed tandem alkyne–alkyne coupling/6‐endo‐dig cyclization sequence was explored and successfully pursued in the synthesis of a dihydropyran ring system. Elaboration of this methodology ultimately led to a concise synthesis of the ring C subunit of bryostatins.

  苔藓抑素是一个结构复杂的大环内酯类，表现出异常广泛的生物活性。这些分子的有限可用性和结构复杂性使得开发有效的全合成尤为重要。本文描述了我们对苔藓抑素全合成的初步努力，其中开发了用于环 C 亚基立体选择性组装的化学选择性和原子经济方法。在二氢吡喃环系统的合成中探索并成功地探索了Pd 催化的串联炔 - 炔偶联/6- endo - dig环化序列。这种方法的详细说明最终导致了苔藓抑素环 C 亚基的简明合成。
• Zinc-Acetic Acid Reductive Cyclisation in a Two-Step Synthesis of the S1-N10 Nine-Membered Lactone Core of<i>ent-</i>Griseoviridin
  作者：Louis Ricard、Janick Ardisson、Grégory Chaume、Carine Kuligowski、Sophie Bezzenine-Laffolée、Ange Pancrazi

  DOI：10.1055/s-2004-834899

  日期：——

  The synthesis of the S1-N10 nine-membered lactone core 28 of ent-griseoviridin is reported. Starting from cystine derivative 25, encompassing a terminal ynoate, treatment under Zn/ AcOH conditions led to the formation of lactone 28 in 12% yield. Therefore, the lactone moiety of ent-griseoviridin is obtained in 10.7% overall yield for two steps. An access to the corresponding 5-epi-griseoviridin lactone

  报道了 ent-griseoviridin 的 S1-N10 九元内酯核心 28 的合成。从胱氨酸衍生物 25 开始，包括末端乙炔酸酯，在 Zn/AcOH 条件下处理导致以 12% 的产率形成内酯 28。因此，通过两步获得 ent-griseoviridin 的内酯部分的总产率为 10.7%。还描述了获得相应的 5-表灰葡萄苷内酯 29。
• Divergent total syntheses of five illudalane sesquiterpenes and assignment of the absolute configuration
  作者：Zhixiong Zeng、Yifan Zhao、Yandong Zhang

  DOI：10.1039/c9cc00933g

  日期：——

  Concise, divergent total syntheses of five bioactive illudalane sesquiterpenes have been achieved. Our synthesis features an intermolecular [2+2+2] cycloaddition, and a lactone-directed aromatic C–H oxygenation to generate a temporary phenolic hydroxyl group which enables regioselective methylation. Furthermore, the absolute configuration of radulactone was assigned by chemical synthesis.

  五个生物活性的伊杜鲁烷倍半萜的简明，不同的总合成方法已经实现。我们的合成具有分子间[2 + 2 + 2]环加成和内酯导向的芳香族C–H氧合作用，以生成临时的酚羟基，从而实现区域选择性的甲基化。此外，通过化学合成确定了Radulactone的绝对构型。
• [EN] HETEROCYCLES AS PROTEIN KINASE INHIBITORS<br/>[FR] HÉTÉROCYCLES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：AMGEN INC

  公开号：WO2009143477A1

  公开（公告）日：2009-11-26

  Selected fused imidazole or triazole derivatives are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的融合咪唑或三唑衍生物对于预防和治疗疾病，如HGF介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药用可接受盐，以及用于预防和治疗涉及癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的工艺以及在此类工艺中有用的中间体。